Table 2.

Incidence and RR for high-grade proteinuria with bevacizumab according to dosages and tumor types

CategoriesNo. of StudiesBevacizumab (Events/Sample Size)Control (Events/Sample Size)Incidence (%; 95% CI)RR (95% CI)
Overall16186/648224/57862.2 (1.2 to 4.3)4.79 (2.71 to 8.46)
2.5 mg/kg per wk759/332419/33021.2 (0.3 to 4.7)2.62 (1.61 to 4.28)
5.0 mg/kg per wk10127/29085/28313.0 (1.5 to 5.7)8.56 (4.09 to 17.92)
CRC653/298519/29731.4 (0.2 to 7.6)2.52 (1.54 to 4.15)
NSCLC218/10860/7671.6 (0.4 to 6.1)12.59 (1.67 to 94.80)
RCC278/7039/65310.2 (4.3 to 22.4)48.76 (9.73 to 244.40)
Breast cancer316/10910/7941.1 (0.2 to 5.2)6.26 (1.11 to 35.46)
Pancreatic cancer218/5643/5443.3 (1.9 to 5.5)4.44 (1.40 to 14.11)
Malignant mesothelioma13/531/555.7 (1.8 to 16.1)3.11 (0.33 to 29.0)
  • The incidence and RR were calculated from the trials included in this study by meta-analysis as described in the Concise Methods section.